Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment

美罗华 医学 视神经脊髓炎 内科学 光谱紊乱 期限(时间) 儿科 免疫学 皮肤病科 多发性硬化 淋巴瘤 精神科 物理 量子力学
作者
Suhyun Kim,Yeseul Kim,Gayoung Kim,Na Young Park,Hyunmin Jang,Hyun-June Shin,Jae‐Won Hyun,Ho Jin Kim
出处
期刊:Journal of Neurology, Neurosurgery, and Psychiatry [BMJ]
卷期号:90 (4): 486-487 被引量:24
标识
DOI:10.1136/jnnp-2018-318465
摘要

Rituximab, a chimeric monoclonal antibody that selectively targets CD20+ B cells, has exhibited robust efficacy and an acceptable safety profile in neuromyelitis optica spectrum disorder (NMOSD).1–3 Previously, we reported that the therapeutic response of B cell depletion varied among 100 patients with NMOSD, which resulted from multiple factors including Fc gamma polymorphism, and that monitoring CD27+ memory B cell appears to improve treatment outcomes via individualised treatment.2 Our treatment strategy has also proven to effectively prevent relapse at a lower cumulative dose, compared with the fixed maintenance therapy every 6 months, in a French cohort.4 Currently, we have a group of patients with NMOSD who have undergone long-term rituximab treatment for more than 7 years. We found that retreatment interval became significantly prolonged over time when we targeted depletion of memory B cells. Here, we analysed clinical outcomes and changes in B cell reconstitution over time, following long-term repeated rituximab treatment. Through December 2017, sixty-eight patients with NMOSD had been treated with rituximab for at least 7 years. Twenty-one patients who had been treated with mitoxantrone, prior to rituximab, were excluded; the remaining 47 patients were included. Written informed consent was obtained from all patients. After induction therapy, patients received a single infusion of rituximab, at a dose of 375 mg/m2, as maintenance therapy; this was performed whenever the frequency of re-emerging CD27+ memory B cells in peripheral blood mononuclear cells (PBMC) exceeded 0.05% as revealed by flow cytometry for the initial 2 years, and, subsequently, when the frequency exceeded …

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
野战星完成签到 ,获得积分10
刚刚
江涸完成签到,获得积分10
刚刚
天道酬勤完成签到,获得积分10
1秒前
整齐白秋完成签到 ,获得积分10
1秒前
怡然契完成签到 ,获得积分10
2秒前
Nole的应助被spark采纳,获得10
3秒前
Nole的应助被spark采纳,获得10
3秒前
小绿完成签到 ,获得积分10
4秒前
xue112完成签到 ,获得积分0
6秒前
恒恒666完成签到 ,获得积分10
7秒前
萌兴完成签到 ,获得积分10
7秒前
9秒前
Makubes完成签到,获得积分10
11秒前
朱又炖粉条完成签到,获得积分20
11秒前
white完成签到,获得积分10
13秒前
loga80完成签到,获得积分0
14秒前
qiuy发布了新的文献求助10
14秒前
忆_完成签到 ,获得积分10
14秒前
cling完成签到 ,获得积分10
18秒前
Helium完成签到 ,获得积分10
19秒前
毛啊毛完成签到,获得积分10
19秒前
123完成签到 ,获得积分10
21秒前
24秒前
舟舟完成签到 ,获得积分10
24秒前
勤奋丹翠完成签到 ,获得积分10
25秒前
DKX完成签到 ,获得积分10
26秒前
岁月如歌完成签到 ,获得积分0
27秒前
Sylvia41完成签到,获得积分10
28秒前
广子完成签到,获得积分10
28秒前
Gong完成签到 ,获得积分10
29秒前
哈哈发布了新的文献求助10
30秒前
炙热毛巾完成签到,获得积分10
31秒前
怡然含桃完成签到 ,获得积分10
31秒前
黄橙子完成签到 ,获得积分10
32秒前
seawolf168完成签到,获得积分10
33秒前
周雨森完成签到 ,获得积分10
38秒前
丰富的大地完成签到,获得积分10
38秒前
活泼惜蕊完成签到 ,获得积分10
38秒前
zyyyyyy完成签到,获得积分10
39秒前
玖月完成签到 ,获得积分0
41秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570230
关于积分的说明 21808824
捐赠科研通 7776113
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012